58 terminated. 58 Phase 2, 8 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 58 | Terminated 58 |
| Phase 1 | 8 | Terminated 8 |
| Phase 3 | 5 | Terminated 5 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities VRB-101, Placebo - Obesity, Overweight | Phase 2 | Terminated | Verdiva Bio Dev Limited | 8 | 2026-06-12 | 2026-10-13 |
| A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes LY3549492, Placebo - Obesity, Overweight | Phase 2 | Terminated | Eli Lilly and Company | 1 | 2025-06-19 | 2026-08-31 |
| CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes CK-0045, Placebo - Type 2 Diabetes Mellitus (T2DM), Obesity and Overweight | Phase 2 | Terminated | Cytoki Pharma | 90 | 2024-09-06 | 2026-02-20 |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide - Obesity | Phase 2 | Terminated | BioAge Labs, Inc. | 204 | 2024-06-27 | 2025-03-13 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | Terminated | Alnylam Pharmaceuticals | 49 | 2023-03-10 | 2025-05-07 |
| Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity PF-07081532, Placebo, Rybelsus - Diabetes Mellitus, Obesity | Phase 2 | Terminated | Pfizer | 902 | 2022-10-27 | 2024-08-01 |
| Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese | Phase 2 / Phase 3 | Terminated | Xiaojun Chen | 8 | 2022-05-01 | 2026-06-04 |
| A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 4 | 2022-04-13 | 2023-10-19 |
| Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM MBL949, Placebo - Obesity | Phase 2 | Terminated | Novartis Pharmaceuticals | 126 | 2022-02-10 | 2024-10-09 |
| A Pilot Trial of Nabilone for the Treatment of Obesity Placebo, Nabilone - Obesity | Phase 2 | Terminated | Centre for Addiction and Mental Health | 18 | 2021-09-17 | 2026-04-09 |
| Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects Botox 200 UNT Injection - Obese, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Terminated | Vanderbilt University Medical Center | 4 | 2021-04-29 | 2023-02-28 |
| CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) CBDV Compound, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Eric Hollander | 6 | 2020-11-23 | 2026-05-07 |
| Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients Camostat Mesilate, Artemisia Annua Leaf - Covid19, Diabetes | Phase 2 | Terminated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 246 | 2020-10-05 | 2021-06-21 |
| A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis FT-4101, FT-4101 placebo, Deuterated Water - Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity | Phase 1 / Phase 2 | Terminated | Forma Therapeutics, Inc. | 14 | 2019-05-17 | 2025-10-20 |
| Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 / Phase 3 | Terminated | Millendo Therapeutics SAS | 158 | 2019-03-25 | 2021-02-17 |
| A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Cannabidiol Oral Solution - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-06 | 2023-06-22 |
| Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome Cannabidiol, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 7 | 2018-05-09 | 2023-08-01 |
| Gemcabene for the Treatment of Pediatric NAFLD Gemcabene - Non-Alcoholic Fatty Liver Disease | Phase 2 | Terminated | Emory University | 6 | 2018-03-29 | 2020-12-31 |
| WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism Dalteparin - Cancer, Venous Thromboembolism | Phase 2 | Terminated | Ottawa Hospital Research Institute | 92 | 2018-03-21 | 2024-01-23 |
| A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure LIK066, Placebo, Empagliflozin - Diabetes Mellitus and Heart Failure | Phase 2 | Terminated | Novartis Pharmaceuticals | 125 | 2017-07-25 | 2019-08-28 |
Showing 20 of 58. Sign in to see all of them.
Obesity (52) · Diabetes Mellitus, Type 2 (11) · Hypertension (7) · Diabetes Mellitus (5) · Prader-Willi Syndrome (5) · Weight Loss (4) · Dyslipidemias (3) · Insulin Resistance (3) · Non-alcoholic Fatty Liver Disease (3) · Schizophrenia (3) · Metabolic Syndrome (2) · Prediabetic State (2) · Weight Gain (2) · Adrenal Gland Neoplasms (1)
Nutritional and Metabolic Diseases (58) · Nutrition Disorders (57) · Overnutrition (57) · Pathological Conditions, Signs and Symptoms (54) · Signs and Symptoms (53) · Body Weight (52) · Metabolic Diseases (20) · Glucose Metabolism Disorders (19) · Endocrine System Diseases (18) · Diabetes Mellitus (11) · Cardiovascular Diseases (8) · Nervous System Diseases (8) · Vascular Diseases (8) · Neurologic Manifestations (7)
Cannabidiol (2) · Varenicline (2) · Adrenalectomy (1) · Amlodipine (1) · Behavior Therapy (1) · Betahistine (1) · Botulinum Toxins, Type A (1) · Bupropion (1) · CJC 1295 (1) · CKD732 (1) · Caloric Restriction (1) · Cholecalciferol (1) · Clonidine (1) · Dalteparin (1) · Diet (1)
Radius Pharmaceuticals, Inc. (3) · Eli Lilly and Company (2) · Gary L. Pierce (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · 7TM Pharma A/S (1) · Alnylam Pharmaceuticals (1) · AstraZeneca (1) · BioAge Labs, Inc. (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Centre for Addiction and Mental Health (1) · ConjuChem (1) · Cytoki Pharma (1)
United States (42) · Canada (7) · Germany (3) · Mexico (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Belgium (2) · Bulgaria (2) · Czechia (2) · France (2) · Hungary (2) · Italy (2) · Netherlands (2) · Poland (2)
Gary L Pierce, PhD (3) · Ahmed Elkashef, MD (2) · Anne E Dixon, MD (1) · Bernard Le Foll, MD, PhD (1) · Bruno Geloneze, MD, PhD (1) · Cenk Tek, MD (1) · Ciaran J McMullan, MD, MMSc (1) · Dennis Kim, MD (1) · Dhaval T Patel, M.D. (1)
PMID 39952695, PMID 15030519, PMID 15885816, PMID 17276373, PMID 18434652, PMID 18752857, PMID 19190233, PMID 19475464, PMID 20297950, PMID 21423999, PMID 21799479, PMID 22088584, PMID 22496216, PMID 22689694, PMID 23412700, PMID 23483886, PMID 23734252, PMID 24482677, PMID 25666761, PMID 25816117, PMID 25968622, PMID 26166259, PMID 28325826, PMID 28880869, PMID 29414327, PMID 29992370, PMID 30668322, PMID 31986264, PMID 32031570, PMID 32075786, PMID 32108857, PMID 32109013, PMID 32112977, PMID 32142651, PMID 32167524, PMID 32215618, PMID 32298251, PMID 32338708, PMID 32584326, PMID 36160639, PMID 39415344, PMID 40353878, PMID 41211763, PMID 41388232
2005 (1), 2014 (1), 2016 (1), K23AT004251 (1), K23DA037299 (1), R21AT001190 (1)